A MediCom Oncology Site
This website uses cookies. By using our site you agree to our privacy policy
Username:
Password:
Lost username/password
Create an account
  • Home
  • About Us
    • Contact Us
    • Accreditation
    • MediCom Worldwide, Inc.
  • Reference
    • What is Multiple Myeloma?
    • FAQ Library
    • Clinical Pearls Podcasts
    • COVID-19 Resource Center
  • CE Education
    • Annual Meeting Highlights
    • Accredited E-Newsletter Series
    • Practice Essentials
  • CE for Nurses
    • ONS 2021
  • Resources
    • Web Links
  • Developments in Newly DIagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes
  • National Nurses Month
  • What is Multiple Myeloma
  • The Use of Biosimilars in Hematology/Oncology Practice
  • Biosimilars for Hematologic Malignancies: Dissecting Real-World Evidence and Barriers to Utilization
  • Visit Our FAQ Library Now!
  • Practice Essentials in Multiple Myeloma
What is the significance of minimal residual disease (MRD) as a surrogate marker in myeloma?

Shaji K. Kumar, MD
Clinical Pearls Podcast

The Use of Biosimilars in Hematology/Oncology Practice

Dr. Charles Bennett, Dr. Marc Fishman, and Dr. Kevin Knopf

Are there any concerns or precautions clinicians should be aware of when switching a patient from IV daratumumab to subcutaneous?

Saad Z. Usmani, MD, FACP




What has been the overall impact of safety and efficacy in four-drug regimens compared to three-drug regimens?

Sagar Lonial, MD, FACP
FAQ

Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes

LIVE Webinar - June 2, 2022
12:00 PM ET - 1:00 PM ET

Earn CME/CPE/CNE Credit!
Sagar Lonial, MD, FACP

What is Multiple Myeloma?
Learn more.
MO Signup MailChimp
MediCom Oncology
Subscribe Today to join our twice weekly
MediCom Oncology Digest
mailing list!

Your email address will not be shared with any third party, nor sold

Trending Now

Biosimilars for Hematologic Malignancies: Dissecting Real-World Evidence and Barriers to Utilization

Charles L. Bennett, MD, PhD, MPP; Marc L. Fishman, MD, CM; Kevin Knopf, MD, MPH

Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes

New Date Just Added

LIVE Webinar - June 2nd 12:00 PM ET - 1:00 PM ET Earn CME/CPE/CNE Credit!

Sagar Lonial, MD, FACP

What has been the overall impact of safety and efficacy in four-drug regimens compared to three-drug regimens?

Sagar Lonial, MD, FACP

Are there any concerns or precautions clinicians should be aware of when switching a patient from IV daratumumab to subcutaneous?

Saad Z. Usmani, MD, FACP

What is Multiple Myeloma?

MediCom Worldwide, Inc. Links

ManagingAML.com | ManagingMDS.com | ManagingMPN.com | ManagingLymphoma.com | PracticalOncologist.com | MediComWorldwide.com

©2022 MediCom Worldwide, Inc. All rights reserved
  • Privacy, Terms, and Conditions
  • Contact Us